The Californian company is kicking off a webinar training program for physical therapists
Featured articles
The company’s plans to cap its fees charged to restaurants and launch a marketplace for eateries...
There were noticeable increases in the body’s natural killer cells in the first two patients treated
The company has entered the 2019 calendar year in a strong position with a focus on pursuing...
Efthymiadis is president of the Hellenic Crop Protection Association
If the pivotal Phase 3 PRECISION-AF clinical trial is successful and Gencaro gets regulatory...
Featured companies
Redx Pharma was formed in 2010 and is an established drug discovery and development company ba...
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeuti...
Tissue Regenix Group plc is a pioneering, international medical technology company, leading th...
![cdy[LOGO]200x100.jpg](/thumbs/upload/Company/Logo/2016_10//200x200_cdy%5BLOGO%5D200x100.jpg){kind=logo}
Cellmid Ltd (ASX:CDY) is an Australian life sciences company with lead programs in multiple di...
ImmunoPrecise Antibodies Ltd. is a public company listed on the TSX Venture Exchange (TSXV: IP...
Shield Therapeutics is a high potential, commercial stage specialty-pharma company. We pride o...
Global biotech Newswire
The Californian company is kicking off a webinar training program for physical therapists
The company’s plans to cap its fees charged to restaurants and launch a marketplace for eateries...
The AIM-listed clinical stage biotechnology said its company broker, Novum Securities issued...
“Building on the momentum generated by existing and new contracts as well as success in...
There were noticeable increases in the body’s natural killer cells in the first two patients treated
OptiBiotix chief executive Stephen O’Hara said: “This is a significant achievement and a major...
The company has entered the 2019 calendar year in a strong position with a focus on pursuing...
Australian-based YPB Group said Namaste will apply its authenticity product markers to all...
Efthymiadis is president of the Hellenic Crop Protection Association
Executive video interviews
Faron Pharmaceuticals Ltd (LON:FARN) says early results from a proof of concept trial...
OptiBiotix Health plc (LON:OPTI) said its cholesterol product had been generally...
CannTrust Holdings Inc (OTCMKTS:CNTTF) (TSE:TRST) CEO Peter Aceto tells Proactive...
AUM Biosciences CEO Vishal Doshi sat down with Proactive Investors at the BIO CEO and...
ReNeuron Group PLC (LON:RENE) said its cell-based therapy has shown signs that it can...
CytoDyn Inc (OTCQB:CYDY) CEO Dr. Nader Pourhassan and Chief Medical Officer Dr. Richard...
BioCorRx Inc (OTCQB: BICX) CEO Brady Granier tells Proactive Investors the...
Parkway Clinical Laboratories Vice President of Lab Operations and Director of Research...
Biocure Technologies (CSE:CURE-OTCQB-BICTF) Director and Professor at the University of...
Dr Cath O'Neill, CEO of SkinBioTherapeutics PLC (LON:SBTX), says her successor...
AdAlta Ltd (ASX: 1AD) CEO Sam Cobb speaks to Proactive Investors about the biotech's...
Anima Biotech CEO Yochi Slonim sat down with Proactive Investors at the BIO CEO &...
Big picture investment ideas in Biotech Capital
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled...
Results from an eight-year clinical extension study showed that ChondroMimetic was able to...
Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment...
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage...
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and...
The company’s digital platform and Artificial Intelligence (AI) software manages and helps...
“If successful, this platform [AP103] has potential in other genetic skin conditions and beyond”
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead...
The cancer detection device is on track to finish a key clinical study in the first quarter of...
Capital Network Research
Shield Therapeutics PLC - Feraccru: a potential game changer in the...
January 18 2019
Feraccru is a unique, non-salt, formulation oral iron: strong...
Avacta Group - Maximising Affimer's potential across therapeutics and...
October 03 2018
Over the last year or so, management has delivered significant progress in bringing their...
Judges Scientific PLC - 2018 Interim Results
September 21 2018
Judges Scientific reported results for the first half of 2018. The period included a...
Legendary Investments - Hidden value potential
September 03 2018
Legendary Investments (LON:LEG) creates value through privately held and pre-market...
Avacta Group - Exciting partnership with Bach BioSciences
July 30 2018
Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with...
Avacta Group - Rapid Progress of Immuno-oncology Programs
April 16 2018
KEY INVESTOR MESSAGES
Faster than expected development of the second immuno-oncology...
Partners:
